SARS-CoV-2 Variant PJ.2.1: New Genetic Mutations, Transmission Prospects, and Immune Response

  Share :          
  132

The PJ.2.1 variant refers to a new lineage of SARS-CoV-2 that first emerged in Canada in May 2026 and was classified as a "saltation variant" due to its acquisition of a large number of genetic changes at once. Preliminary scientific literature suggests that its rapid spread may be attributed primarily to enhanced ACE2 receptor binding affinity rather than exceptional immune evasion capability, and current clinical data have not demonstrated evidence that it causes more severe disease. Origin and Geographic Spread The PJ.2.1 variant descended from lineage MC.10.1.7 (a sublineage of JN.1). The first sample was detected in Ontario, Canada, on 2 May 2026. Genomic surveillance data from Public Health Ontario indicate that the proportion of PJ.2.1 rose from 16.9% (the preceding four-week period) to 25.2% (between 20 September and 17 October) among sequenced SARS-CoV-2 samples. It subsequently spread rapidly in the United States, where wastewater analysis showed it had become the fastest-growing variant in the country. Cases have also been reported in the United Kingdom, France, Spain, Singapore, Australia, New Zealand, Israel, and elsewhere, with evidence of local transmission in several regions of Spain. Molecular Characteristics and Mechanism of Spread The defining feature of the PJ.2.1 variant lies in its multiple mutations in the Spike protein. Laboratory studies have shown that PJ.2.1 is less susceptible to inhibition by ACE2-targeting antibodies compared with other variants, suggesting that its Spike protein may enhance the efficiency of ACE2 receptor binding. This molecular adaptation may confer an advantage in entering host cells, partly explaining its rapid spread. Regarding immune evasion, available research findings indicate that PJ.2.1 did not exhibit notable antibody evasion capacity compared with most other variants. For individuals who received an mRNA booster updated to LP.8.1, the susceptibility of PJ.2.1 to neutralizing antibodies was only 1.8-fold lower than that of the reference LP.8.1 strain. This suggests that its primary mechanism of spread may be linked to increased receptor binding avidity rather than immune evasion. Clinical Manifestations To date, there are no specific unique symptoms for PJ.2.1. The World Health Organization has warned that its symptoms overlap substantially with influenza and the common cold, making clinical differentiation difficult. Possible common symptoms include: fever, cough, sore throat, runny or stuffy nose, headache, muscle aches, and fatigue. Some experts have suggested that severe sore throat and prolonged post-recovery fatigue may be associated with this variant, but these observations have not yet been established as distinctive clinical features. It must be emphasized that variant identification relies on genetic sequencing; rapid antigen tests or standard PCR tests can only confirm SARS-CoV-2 infection and cannot determine whether the variant is PJ.2.1. Disease Severity and Immune Response Current assessments by the World Health Organization and health authorities in several countries conclude that there is no evidence that PJ.2.1 causes more severe disease than other circulating variants. No increase in hospitalization, intensive care admission, or mortality rates has been observed. Regarding vaccines, preliminary studies have shown that the mRNA vaccine updated to XFG (approved for the 2026/2027 season) can effectively induce the production of neutralizing antibodies against PJ.2.1. In a study of 22 participants, booster vaccination with XFG increased neutralizing antibody titers against PJ.2.1 by 2.8-fold. This provides a reasonable basis for the vaccine update strategy. Conclusion The PJ.2.1 variant represents a typical case of SARS-CoV-2 continuing to evolve under immune pressure. Its main characteristics are: enhanced ACE2 receptor binding affinity that promotes faster spread, no marked enhancement of immune evasion capacity, and current clinical data do not support increased severity. Response strategies should remain focused on genomic surveillance (particularly tracking potential new mutations), vaccine updating, and protecting vulnerable populations (older adults and immunocompromised individuals). As research literature on this variant is still in the preprint or early publication stage and has not undergone full peer review, the above conclusions may require updating as data accumulate. Al-Mustaqbal University The First University in Iraq